FeesSafety
Pluang+

CMS final rule extends payment support for Lantheus' PYLARIFY TruVu diagnostic imaging through 2029

Market News
05 Nov 2026, 14:15 WIB
GlobeNewsWire
View Source
Bullish
CMS final rule extends payment support for Lantheus' PYLARIFY TruVu diagnostic imaging through 2029

The Centers for Medicare & Medicaid Services (CMS) finalized its 2027 outpatient payment rule, maintaining separate reimbursement for advanced diagnostic radiopharmaceuticals. Lantheus' PYLARIFY TruVu (piflufolastat F 18) will retain Transitional Pass-Through payment status through September 30, 2029, ensuring stable hospital reimbursement. Additionally, PYLARIFY TruVu receives a permanent HCPCS code A9613 effective October 1, 2026, simplifying billing. This supports patient access to advanced prostate cancer imaging and reflects CMS' recognition of the role of innovative radiopharmaceuticals in improving diagnostic care.

Lantheus' diagnostic radiopharmaceuticals are highlighted alongside Pluang's health sector market data for context. For readers following health stocks, as of Nov 05, 2026 19:01 WIB, 94 of 150 priced US health-sector stocks rose while 48 fell. Notable movers include ALMS at USD 6.20 with a -5.34% change and a typical hold time of 21 days, OSCR at USD 36.95 with a +5.00% change and Pluang order activity showing 41% Sell / 59% Buy, and ADPT at USD 27.99 with a +4.79% change and 100% Buy order activity, held typically for 37 days.

More News

Opus Genetics completes dosing in Phase 1/2 trial for gene therapy targeting inherited retinal diseases

Opus Genetics completes dosing in Phase 1/2 trial for gene therapy targeting inherited retinal diseases

Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...

Market News
Bullish
35 minutes ago
Perimeter Group reports Q3 2026 net income of $304.5M, driven by strong sales and acquisitions.

Perimeter Group reports Q3 2026 net income of $304.5M, driven by strong sales and acquisitions.

Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...

Company Fundamentals
Bullish
1 hour ago
ACM Research Q3 revenue jumps 37%, raises 2026 outlook on strong semiconductor demand

ACM Research Q3 revenue jumps 37%, raises 2026 outlook on strong semiconductor demand

ACM Research reported a 37% year-over-year revenue increase to $367.7 million in Q3 2026, driven by strong demand in electrochemical plating (ECP) and advanced packaging technologies. The company is expanding manufacturing capacity and global sales e...

Company Fundamentals
Bullish
2 hours ago
Purple renews WiFi partnership with Lucid Motors in Riyadh, enhancing connectivity for staff and visitors.

Purple renews WiFi partnership with Lucid Motors in Riyadh, enhancing connectivity for staff and visitors.

Purple has renewed its partnership with Lucid Motors to continue providing WiFi services across Lucid's operations in Riyadh. This renewal ensures that both staff and visitors have secure and easy internet access, supporting Lucid's growing presence ...

Market News
Bullish
2 hours ago
Investec Bank discloses share dealings in SThree Plc on Nov 4, 2026, as joint broker.

Investec Bank discloses share dealings in SThree Plc on Nov 4, 2026, as joint broker.

Investec Bank Plc, acting as joint broker to SThree Plc, disclosed public dealings involving the purchase and sale of 118,333 ordinary shares each on November 4, 2026. The transactions were conducted within a price range of 295 to 304 per share. Ther...

Market News
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App